The above results collectively suggested that combination therapy can reduce hyperglycemia-induced myocardial fibrosis by increasing the expression of PPAR-γ and inhibiting the activity of NF-κB in myocardial tissues of DCM rats, thereby controlling inflammatory response. The gene discussed is NFKB1; the disease is familial dilated cardiomyopathy.